A discussion of the regulatory history behind audit trails and its interpretation as it relates to clinical research data originating or residing in EDC or eCOA systems.
What the industry’s most inspiring technology innovators see coming in 2022.
Increased data output from the use of devices can accelerate trials for this therapeutic area in need of new therapies.
Study seeks to understand how different forms of data meet the needs of researchers.
In an era of rising healthcare expenses, reassurance about costs for patients in diverse communities is particularly important.
Digital biomarkers provide a pathway to the future where clinical trial sponsors can potentially benefit from reduced trial duration and sample size. Learn more about these benefits from a simulated study.
While televisits can address many medical concerns, one frequent reservation expressed by healthcare professionals is that patients during these televisits tend to present too narrow a picture of their clinical condition-resulting in non-comprehensive medical assessments.
Improvements in data management and collaboration forge path to greater efficiency.
The answers to meeting biosimulation's growing demand for talent may lie in Africa.
DCTs can be a great tool for small-to-midsize pharma and biotech companies despite misconceptions of them being advantageous for only Big Pharma.
Exploring stat-based testing for variables that identify deliberate data manipulation in clinical trials.
DCTs and RWD among topics for industry to focus on moving into 2023.
Machine learning can help investors dive deeper into trial data to evaluate the true potential of an asset and uncover new hidden opportunities.
The complexities behind these translations require specialized personnel who are nuanced in both medical cultures.
Expectations for trial design will continue to change, and it’s critical that IRT vendors continue to listen to their customers and evolve their offerings accordingly.
FDA’s new voluntary pilot program is designed to help clinicians select appropriate cancer treatments for patients.
Survey data shows individuals are not informed on how COVID-19 could affect their conditions.
At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Today's reality and the hopes of tomorrow of the COVID-19 pandemic—an updated mapping of vaccines authorized by regulatory bodies and those close to it.
A win-win-win for sites, sponsors, and referral partners.
Approaches sponsors, CROs, and investigators can take from the DMD experience.
Balancing these tools with operational efficiencies can aid CROs in meeting the evolving needs of sponsors.
As market factors drive the rapid growth of decentralized clinical trials, organizations should embrace risk-based quality management to evaluate the new dimensions of risk and ensure effective oversight of disparate data sources, writes John Hall.
While televisits can address many medical concerns, one frequent reservation expressed by healthcare professionals is that patients during these televisits tend to present too narrow a picture of their clinical condition-resulting in non-comprehensive medical assessments.
Sites not expected to fade away even as DCTs continue to grow past COVID-19.
Clinical research sites feel growing pressure to perform work in a compliant manner while keeping pace with stakeholder information exchange workstreams, but lack the consistent processes to do so.
Spearheaded by disease foundations, the creation of clinical registries is streamlining data collection and driving informed decisions.